Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CLEU20105/ S1905/ Kristen O'Dwyer

Basic Study Information

Purpose:
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search